Sun Pharma served with tax demand of Rs 1.11 crore

Published On 2024-05-01 07:50 GMT   |   Update On 2024-05-01 07:50 GMT

Mumbai: Sun Pharmaceutical Industries has been served with a tax demand of over Rs 1.11 crore by authorities, citing disallowed input tax credit.As per the recent BSE filing, the company has received an order from the Joint Commissioner, CGST and Central Excise, passed under the GST Act, raising a demand of Rs 1,11,60,156, imposing a penalty of Rs 11,16,016 and interest as applicable.The...

Login or Register to read the full article

Mumbai: Sun Pharmaceutical Industries has been served with a tax demand of over Rs 1.11 crore by authorities, citing disallowed input tax credit.

As per the recent BSE filing, the company has received an order from the Joint Commissioner, CGST and Central Excise, passed under the GST Act, raising a demand of Rs 1,11,60,156, imposing a penalty of Rs 11,16,016 and interest as applicable.

The reason for the order is disallowed input tax credit on account of inadmissible transitional credit, it added.
"There is no material impact on financial, operation or other activities of the company," the filing stated.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Read also: Sun Pharma Advanced Research Company halts Parkinson's disease drug trial


Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News